Akcea Therapeutics Inc
AKCA
AKCA was delisted on the 9th of October, 2020.
0 hedge funds and large institutions have $0 invested in Akcea Therapeutics Inc in 2020 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 98 closing their positions.
15.6% less ownership
Funds ownership: 15.6% → 0% (-16%)
100% less funds holding
Funds holding: 98 → 0 (-98)
100% less capital invested
Capital invested by funds: $287M → $0 (-$287M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 98
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$104M |
| 2 |
BlackRock
New York
|
-$39.9M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$24.9M |
| 4 |
GF
Gabelli Funds
Rye,
New York
|
-$10.9M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$8.13M |
AKCA Hedge Fund Activity: Q4 2020 in Review
0 of the 5,677 institutional investors tracked by Wall St. Rank reported a position in Akcea Therapeutics Inc (AKCA) for Q4 2020, worth a combined $0 — down 100% from $287M a quarter earlier.
Sellers outnumbered buyers: 98 funds closed out of AKCA and 0 opened new positions — a net loss of 98 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Fidelity Investments, exiting entirely with an estimated $104M sold.
- 0 institutional investors held Akcea Therapeutics Inc (AKCA) as of Q4 2020, down from 98 in Q3 2020.
- Funds reported $0 of Akcea Therapeutics Inc stock for Q4 2020, down 100% quarter-over-quarter.
- 0 funds opened new Akcea Therapeutics Inc positions in Q4 2020 and 98 closed out, a net change of -98 holders.
- The largest Akcea Therapeutics Inc seller in Q4 2020 was Fidelity Investments, an estimated $104M sold.
Based on aggregated 13F filings for Q4 2020.